Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity

2004 ◽  
Vol 5 (11) ◽  
pp. 1143-1148 ◽  
Author(s):  
Christopher M Smith ◽  
Nicholas S Wilson ◽  
Jason Waithman ◽  
Jose A Villadangos ◽  
Francis R Carbone ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Cd4 T Cell ◽  
Cell Immunity

scholarly journals Simultaneous Induction of CD4 T Cell Tolerance and CD8 T Cell Immunity by Semimature Dendritic Cells

2005 ◽  
Vol 174 (7) ◽  
pp. 3941-3947 ◽  
Author(s):  
Petra Kleindienst ◽  
Carsten Wiethe ◽  
Manfred B. Lutz ◽  
Thomas Brocker
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Cd4 T Cell ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Simultaneous Induction ◽  
Cell Immunity

scholarly journals Skin-Derived Dendritic Cells Induce Potent CD8+ T Cell Immunity in Recombinant Lentivector-Mediated Genetic Immunization

Immunity ◽  
2006 ◽  
Vol 24 (5) ◽  
pp. 643-656 ◽  
Author(s):  
Yukai He ◽  
Jiying Zhang ◽  
Cara Donahue ◽  
Louis D. Falo
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Genetic Immunization ◽  
Cell Immunity

scholarly journals DC-Based Vaccines for Cancer Immunotherapy

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 706
Author(s):  
Chunmei Fu ◽  
Li Zhou ◽  
Qing-Sheng Mi ◽  
Aimin Jiang
Keyword(s):  
Clinical Trials ◽  
T Cells ◽  
Dendritic Cells ◽  
T Cell ◽  
Cd8 T Cells ◽  
Critical Role ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Cell Responses ◽  
Cell Immunity

As the sentinels of the immune system, dendritic cells (DCs) play a critical role in initiating and regulating antigen-specific immune responses. Cross-priming, a process that DCs activate CD8 T cells by cross-presenting exogenous antigens onto their MHCI (Major Histocompatibility Complex class I), plays a critical role in mediating CD8 T cell immunity as well as tolerance. Current DC vaccines have remained largely unsuccessful despite their ability to potentiate both effector and memory CD8 T cell responses. There are two major hurdles for the success of DC-based vaccines: tumor-mediated immunosuppression and the functional limitation of the commonly used monocyte-derived dendritic cells (MoDCs). Due to their resistance to tumor-mediated suppression as inert vesicles, DC-derived exosomes (DCexos) have garnered much interest as cell-free therapeutic agents. However, current DCexo clinical trials have shown limited clinical benefits and failed to generate antigen-specific T cell responses. Another exciting development is the use of naturally circulating DCs instead of in vitro cultured DCs, as clinical trials with both human blood cDC2s (type 2 conventional DCs) and plasmacytoid DCs (pDCs) have shown promising results. pDC vaccines were particularly encouraging, especially in light of promising data from a recent clinical trial using a human pDC cell line, despite pDCs being considered tolerogenic and playing a suppressive role in tumors. However, how pDCs generate anti-tumor CD8 T cell immunity remains poorly understood, thus hindering their clinical advance. Using a pDC-targeted vaccine model, we have recently reported that while pDC-targeted vaccines led to strong cross-priming and durable CD8 T cell immunity, cross-presenting pDCs required cDCs to achieve cross-priming in vivo by transferring antigens to cDCs. Antigen transfer from pDCs to bystander cDCs was mediated by pDC-derived exosomes (pDCexos), which similarly required cDCs for cross-priming of antigen-specific CD8 T cells. pDCexos thus represent a new addition in our arsenal of DC-based cancer vaccines that would potentially combine the advantage of pDCs and DCexos.

scholarly journals Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

Cell ◽  
2019 ◽  
Vol 177 (3) ◽  
pp. 556-571.e16 ◽  
Author(s):  
Mikhail Binnewies ◽  
Adriana M. Mujal ◽  
Joshua L. Pollack ◽  
Alexis J. Combes ◽  
Emily A. Hardison ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
T Cell Immunity ◽  
Cd4 T Cell ◽  
Cell Immunity

scholarly journals Identification of immunogenic LY6K long peptide encompassing both CD4+and CD8+T-cell epitopes and eliciting CD4+T-cell immunity in patients with malignant disease

2014 ◽  
Vol 3 (3) ◽  
pp. e28100 ◽  
Author(s):  
Yusuke Tomita ◽  
Akira Yuno ◽  
Hirotake Tsukamoto ◽  
Satoru Senju ◽  
Yasuhiro Kuroda ◽  
...  
Keyword(s):  
T Cell ◽  
Malignant Disease ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Cd4 T Cell ◽  
T Cell Epitopes ◽  
Cell Immunity

scholarly journals Identification of CDCA1-derived long peptides bearing both CD4+and CD8+T-cell epitopes: CDCA1-specific CD4+T-cell immunity in cancer patients

2013 ◽  
Vol 134 (2) ◽  
pp. 352-366 ◽  
Author(s):  
Yusuke Tomita ◽  
Akira Yuno ◽  
Hirotake Tsukamoto ◽  
Satoru Senju ◽  
Sachiko Yoshimura ◽  
...  
Keyword(s):  
T Cell ◽  
Cancer Patients ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Cd4 T Cell ◽  
T Cell Epitopes ◽  
Cell Immunity
Sign in / Sign up

Export Citation Format

Share Document